Radiopharmaceuticals for Neuroendocrine Tumors

Re I. Chin, Francis S. Wu, Yusuf Menda, Hyun Kim

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that originate in endocrine tissues throughout the body. Peptide receptor radionuclide therapy (PRRT) has emerged as a promising therapeutic option for patients with locally advanced and/or metastatic disease refractory to standard of care treatment. The landmark international phase III NETTER-1 trial led to the approval of 177Lu-DOTATATE (Lutathera) in the treatment of somatostatin receptor-positive gastroenteropancreatic NETs. Similarly, data from the multicenter, phase II Study IB12B led to the approval of meta-[131I]Iodo-Benzyl-Guanidine (I31I-MIBG) for treatment of iobenguane scan-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma. With the clinical approval of these novel radiopharmaceuticals for managing select patients with NETs, additional studies are needed to refine patient selection, predict and assess therapy response, and optimize radiopharmaceutical delivery and clinical outcomes.

Original languageEnglish
Pages (from-to)60-70
Number of pages11
JournalSeminars in Radiation Oncology
Issue number1
StatePublished - Jan 2021


Dive into the research topics of 'Radiopharmaceuticals for Neuroendocrine Tumors'. Together they form a unique fingerprint.

Cite this